How Much Does Low-Dose Naltrexone Cost in Wyoming in 2026?

Wyoming Cash Prices for Low-Dose Naltrexone in 2026

The average cash price for compounded low-dose naltrexone across Wyoming pharmacies sits at roughly $50 per month in 2026. That figure reflects 503A compounding pharmacy pricing for a standard 1.5 to 4.5 mg oral capsule, dispensed as a 30-day supply. Annual out-of-pocket cost runs about $600 for patients paying without insurance.

LDN is not commercially manufactured at low doses. The FDA approved naltrexone at 50 mg for opioid use disorder and alcohol dependence, but the 1.5 to 4.5 mg doses used off-label require a compounding pharmacy to prepare. This means Wyoming patients cannot use standard manufacturer coupons or large-chain pharmacy discount cards that apply to commercially available tablets.

Price variation between compounding pharmacies in Wyoming tends to be modest. Some pharmacies charge $40 per month, others $60, depending on capsule strength and whether the pharmacy ships by mail or dispenses in person. Patients in smaller towns like Sheridan, Rock Springs, or Riverton may find that out-of-state 503A pharmacies licensed to ship into Wyoming offer competitive pricing.

A pilot study by Younger et al. (2009, N=10) first demonstrated that LDN at 4.5 mg reduced fibromyalgia symptoms by 30% compared to placebo, sparking broader clinical interest in the drug at low doses. That early evidence helped drive demand for compounded formulations, though the small sample size means larger confirmatory trials remain necessary.

Wyoming Medicaid and LDN: What's Covered

Wyoming Medicaid does not cover low-dose naltrexone for off-label indications such as fibromyalgia, chronic pain, or autoimmune conditions. This policy aligns with most state Medicaid programs, which restrict naltrexone coverage to its FDA-approved indications at 50 mg.

The gap between clinical use and coverage creates a real burden. Wyoming's Medicaid population skews toward rural communities where chronic pain conditions are common and specialist access is limited. A 2021 analysis published in the Journal of Pain Research found that off-label LDN use grew by over 200% between 2015 and 2019 nationally, yet insurance reimbursement policies have not kept pace with prescribing trends.

Wyoming Medicaid does cover naltrexone 50 mg tablets for substance use disorders. Patients prescribed both the standard-dose formulation for an approved indication and LDN for a separate off-label condition should be aware these are distinct prescriptions requiring different pharmacies (retail vs. compounding).

Attempting prior authorization for LDN through Wyoming Medicaid is possible but rarely successful. Providers sometimes submit appeals citing clinical necessity, particularly for patients with documented treatment failures on conventional therapies. Success rates for these appeals remain low.

Private Insurance Coverage in Wyoming

Most private insurance plans in Wyoming, including those offered through Blue Cross Blue Shield of Wyoming, Cigna, and UnitedHealthcare marketplace plans, do not routinely cover compounded LDN. The primary barrier is twofold: LDN is prescribed off-label, and compounded medications fall outside standard formulary structures.

Some patients have obtained partial reimbursement. The path typically involves a prescriber submitting a prior authorization request with supporting clinical documentation. A 2014 review in Pharmacotherapy summarized the mechanistic basis for LDN's anti-inflammatory effects through transient opioid receptor blockade and upregulation of endogenous opioid signaling. That body of evidence, while growing, has not reached the threshold most insurers require for formulary inclusion.

Self-funded employer plans occasionally offer more flexibility than fully insured marketplace products. Wyoming employers with self-funded health plans can direct their plan administrators to cover specific compounded medications. Patients employed by state agencies or larger Wyoming employers should review their plan's compounding pharmacy benefit or contact their benefits coordinator directly.

For the roughly 26% of Wyoming residents on employer-sponsored insurance, the practical advice is straightforward. Call the pharmacy benefit manager listed on the back of the insurance card, ask whether compounded naltrexone carries any coverage, and request the prior authorization form if the answer is ambiguous. The call takes ten minutes and could save $600 a year.

503A Compounding Pharmacies in Wyoming

Compounded LDN is legal in Wyoming through 503A compounding pharmacies. These pharmacies operate under Section 503A of the Federal Food, Drug, and Cosmetic Act, which permits patient-specific compounding based on a valid prescription. Wyoming's Board of Pharmacy recognizes this federal framework and licenses both in-state compounders and out-of-state pharmacies that ship into the state.

Wyoming has a limited number of brick-and-mortar compounding pharmacies. Cheyenne and Casper host the largest concentration. Patients in more remote areas (think Thermopolis, Lander, or Evanston) typically rely on mail-order compounding pharmacies based in states like Colorado, Texas, or Florida.

When selecting a compounding pharmacy, verify three things. First, confirm the pharmacy holds a valid Wyoming license or is registered with the Wyoming Board of Pharmacy for nonresident dispensing. Second, ask whether the pharmacy follows USP <795> standards for nonsterile compounding. Third, request a Certificate of Analysis for the naltrexone powder used in compounding, which confirms potency and purity.

503B outsourcing facilities represent a separate regulatory category under federal law. These facilities can compound without patient-specific prescriptions and are FDA-registered. A small number of 503B facilities produce LDN capsules, though pricing from 503B sources does not differ dramatically from 503A pharmacies for this particular drug. The FDA maintains a registry of registered outsourcing facilities that patients can search.

Telehealth Prescribing of LDN in Wyoming

Telehealth prescribing of low-dose naltrexone is legal in Wyoming. The state permits licensed providers to prescribe LDN via video or audio consultation without requiring an in-person visit first. This policy makes LDN accessible to patients across Wyoming's 97,813 square miles, the least densely populated state in the country.

Wyoming's telehealth laws were expanded during the COVID-19 pandemic and many of those expansions became permanent through subsequent legislation. Providers licensed in Wyoming (or holding a compact license recognized by the state) can evaluate, diagnose, and prescribe through telehealth platforms. LDN falls under standard prescribing authority since it is not a controlled substance at any dose.

A typical telehealth LDN consultation costs between $75 and $200 for the initial visit, with follow-ups ranging from $50 to $100. Some telehealth platforms bundle the consultation fee with pharmacy coordination, meaning the provider sends the prescription directly to a partnered compounding pharmacy.

Dr. Jarred Younger, the neuroscientist whose lab at the University of Alabama at Birmingham has published extensively on LDN mechanisms, noted in a 2014 publication that "low-dose naltrexone may attenuate central inflammation by modulating microglial activity in the central nervous system." That mechanism, distinct from naltrexone's action at full opioid-blocking doses, underpins much of the current off-label prescribing for conditions like fibromyalgia and Crohn's disease.

For Wyoming residents, telehealth removes the geographic barrier that previously limited LDN access to those living near urban centers. A rancher in Big Horn County has the same prescribing access as someone in downtown Cheyenne.

How to Reduce Your LDN Costs in Wyoming

Several strategies can lower the effective cost of LDN below the $50 per month average.

Compare multiple compounding pharmacies. Price quotes from three pharmacies typically reveal a $10 to $20 spread per month. Out-of-state mail-order compounders licensed in Wyoming sometimes undercut local pricing due to higher volume.

Ask about 90-day supplies. Some compounding pharmacies offer a per-unit discount for 90-day fills, bringing the monthly cost down to $35 to $45. The trade-off is a larger upfront payment.

Check patient assistance programs. While no manufacturer assistance program exists for compounded LDN (since there is no commercial manufacturer), some compounding pharmacies run their own discount programs for patients who demonstrate financial need. Ask the pharmacy directly.

Use a Health Savings Account (HSA) or Flexible Spending Account (FSA). Compounded LDN prescribed by a licensed provider is an eligible medical expense under IRS rules for HSAs and FSAs. Paying with pre-tax dollars effectively reduces the cost by your marginal tax rate.

Explore clinical trials. ClinicalTrials.gov lists ongoing LDN studies that may provide the medication at no cost. A 2022 randomized controlled trial of LDN for fibromyalgia (N=99) found a statistically significant reduction in pain severity (mean difference of 1.02 points on a 0-10 scale, P=0.003), and similar trials continue to recruit participants.

Wyoming does not currently have a state-run prescription assistance program that covers compounded medications specifically.

LDN Dosing, Safety, and What Wyoming Providers Prescribe

Standard LDN prescribing in Wyoming follows the same protocol used nationally. Most providers start at 1.5 mg taken once nightly and titrate upward to 4.5 mg over two to four weeks. The nightly dosing schedule takes advantage of the drug's short half-life (approximately 4 hours) to produce a transient opioid receptor blockade followed by a rebound increase in endogenous endorphin and enkephalin production.

Side effects at low doses are generally mild. The most commonly reported adverse effects in published studies include vivid dreams, transient headache, and mild nausea during the first one to two weeks. A systematic review in Clinical Rheumatology (2020) covering 89 patients across four trials found no serious adverse events attributable to LDN at doses of 1.5 to 4.5 mg.

The American Academy of Pain Medicine does not yet include LDN in formal clinical guidelines, though individual members have published supportive case series. The Endocrine Society has not issued guidance on LDN specifically, as the drug falls outside traditional endocrine indications.

Prescribers in Wyoming should document the clinical rationale for off-label LDN use in the patient's chart, including prior treatments attempted and the specific condition being targeted. This documentation protects both the provider and the patient, particularly if insurance appeals are attempted later.

Patients taking opioid medications cannot use LDN concurrently. Even at low doses, naltrexone blocks opioid receptors and can precipitate withdrawal in opioid-dependent individuals. A minimum washout period of 7 to 10 days from short-acting opioids (and longer for long-acting formulations) is required before initiating LDN.

Wyoming-Specific Regulatory Considerations

Wyoming's Board of Pharmacy regulates compounding practices within the state and recognizes the federal 503A framework. Compounding pharmacies must maintain proper licensure, and prescriptions for compounded LDN must originate from a provider with an active Wyoming license or a valid compact license.

Wyoming follows the Ryan Haight Act for controlled substance prescribing via telehealth, but naltrexone is not a scheduled controlled substance, so LDN prescribing faces no additional telehealth restrictions beyond standard prescribing authority.

The Wyoming Department of Health has not issued specific guidance on LDN. Patients seeking information about compounding pharmacy complaints or verification can contact the Wyoming Board of Pharmacy directly or search its online license verification tool.

One regulatory detail worth noting: Wyoming permits pharmacists to compound a "reasonable quantity" of LDN in anticipation of prescription orders under 503A rules. This means a compounding pharmacy can maintain a small ready supply, reducing wait times for patients who need the medication promptly. Typical turnaround for a new LDN prescription at a Wyoming compounding pharmacy is one to three business days for in-person pickup and three to five days for mail delivery.

LDN capsules at 4.5 mg taken nightly cost approximately $1.67 per day in Wyoming, or roughly the price of a cup of gas-station coffee in Cheyenne.